Anderson, Lesley

Brenner, Hermann

De Angelis, A.

Holleczek, Bernd

Marcos-Gragera, Rafael

Maynadié, Marc

Minicozzi, Pamela

Monnereau, Alain

Mounier, Morgane

Sant, Milena

Visser, O.

Working Group, EUROCARE-5

Queen's University Belfast Research Portal

Remarkable survival improvement for European patients withhaematological malignancies from 1997 to 2008Minicozzi, P., Sant, M., Mounier, M., Anderson, L., Brenner, H., Holleczek, B., ...  Working Group, E. U. R. O. C.A. R. E. (2014). Remarkable survival improvement for European patients with haematological malignancies from1997 to 2008. Poster session presented at ENCR Scientific Meeting and General Assembly, Ispra, Italy.Document Version:Publisher's PDF, also known as Version of recordQueen's University Belfast - Research Portal:Link to publication record in Queen's University Belfast Research PortalPublisher rightsCopyright 2014 the author.General rightsCopyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or othercopyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associatedwith these rights.Take down policyThe Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made toensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in theResearch Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.Download date:15. Feb. 2017Remarkable survival improvement for European  patients with haematological malignancies  from 1997 to 2008  P Minicozzi,1,* M Sant,1 M Mounier,2 LA Anderson,3 H Brenner,4,5 B Holleczek,6 R Marcos-Gragera,7 M Maynadié,2 A Monnereau,8,9 G Osca-Gelis,7 O Visser,10 R De Angelis,11 and the EUROCARE-5 Working Group.  1 Analytical Epidemiology and Health Impact Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan,  Italy;   2 Registre des hémopathies malignes de Côte d’Or, EA 4184, University of Burgundy and University Hospital of Dijon, Dijon, France; 3 Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland; 4 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DFKZ), Heidelberg, Germany; 5 German Cancer Consortium (DKTK), Heidelberg, Germany; 6 Saarland Cancer Registry, Saarbrücken, Germany; 7 Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute, Girona, Spain; 8 Registre des hémopathies malignes de la Gironde, Institut Bergonié, Bordeaux, France; 9 Centre INSERM U897, CIC, Centre d’Investigation Clinique, Bordeaux, France;10 Comprehensive Cancer Centre the Netherlands, Department of Registration and Research, Utrecht, The Netherlands;11 Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute (CNESPS), Istituto Superiore di Sanità, Roma, Italy  *pamela.minicozzi@istitutotumori.mi.it Objective  Innovative effective treatment for haematological malignancies (HMs) have become available since 2000’s.  The aim of this study was to estimate time trends in population-based survival for 11 lymphoid and myeloid malignancies, in particular for diffuse large B-cell lymphoma (DBLCL), follicular lymphoma (FL), chronic myeloid leukaemia (CML) and acute promyelocytic leukaemia (APL). Materials and methods             Discussion  The increased survival over time is likely attributable linked to the diffusion of targeted and other new effective treatments. The large differences in cancer survival across Europe suggest inequalities in the provision of care and the availability of new treatments. Population-based high resolution studies, collecting data on morphology, treatments and stage, can provide evidence of the above written hypotheses.  Results                          Acknowledgments Compagnia di San Paolo, Fondazione Cariplo, European Commission and Italian Ministry of Health  Paper published in Lancet Oncol 2014;15:931-42 * Not age-standardised estimates 102 European cancer registries (CRs) recording adult HMs cases 35 CRs had continous incident data from 1992 to 2007 5 CRs excluded because: >14% DCO or autopsy >30% cases not microscopically veriefied 30 CRs included in the study Analyses by age at diagnosis Analyses by  European area • 5-year relative survival • hybrid approach • trends by 3-year periods (1997-99, 2000-02, 2003-05, 2006-08)  

Remarkable survival improvement for European patients with haematological malignancies from 1997 to 2008

Remarkable survival improvement for European patients with haematological malignancies from 1997 to 2008

Abstract

Similar works

Full text

Available Versions

Queen's University Belfast Research Portal